For full functionality of this website it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser

Session Details

Roundtable Session: What is the future of virus-specific T cells?
Friday, September 8, 2023 09:15 AM - 10:15 AM  
337 AB
Moderator
Patrick Hanley, PhD, Children's National Hospital, USA

Panelists
Kevin Curran, MD, Memorial Sloan Kettering Cancer Center, USA
Allyson Flower, MD, New York Medical College, USA
Michael Keller, MD, Children's National, USA


With the advent of two (hopefully) soon-to-be approved antiviral T cell products, the emergence of Letermovir, and (in some cases) a move away from T cell depletion…where does that leave the field? Some individuals are working on point of care donor-derived virus-specific T cells and some have just finished nationwide multi-center clinical trials for off-the-shelf VSTs, thus a discussion of the pros and cons of these approaches and whether there is still a need today and in the future.

Patrick Hanley PhD
Chief and Director, Cellular Therapy Program; Associate Professor of Pediatrics
Children's National Hospital
Moderator


Michael Keller
Associate Professor of Pediatrics, Division of Allergy & Immunology, Center for Cancer and Immunology Research, Director, Jeffrey Modell Diagnostic and Research Center, For Primary Immunodeficiencies
Children's National Hospital
Moderator & Panelist


Kevin Curran MD
Pediatric Hematologist-Oncologist
Memorial Sloan Kettering Cancer Center
Panelist


Allyson Flower MD
Assistant Professor of Pediatrics, Division of PEdiatric Hematology, Oncology, Stem Cell Transplant
New York Medical College
Panelist